Accompanying slides from the TREK-AD topline data readoutVIEW MORE
Eblasakimab Monthly Dosing Shows Potential for Best-in-class Therapy in Positive Phase 2b Study in Atopic DermatitisVIEW MORE
ASLAN Pharmaceuticals Enters into a Strategic Licensing Deal with Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in JapanVIEW MORE
ASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in two Late-breaking Presentations at the 1st International Societies for Investigative Dermatology MeetingVIEW MORE
ASLAN Pharmaceuticals Announces Four Abstracts on Eblasakimab and Farudodstat, Including Two Late-Breakers, to be Presented at The 1st International Societies For Investigative Dermatology MeetingVIEW MORE
ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts For Poster Presentation at The 1st International Societies For Investigative Dermatology MeetingVIEW MORE
ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis PatientsVIEW MORE
ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis PatientsVIEW MORE
ASLAN Pharmaceuticals Announces Acceptance of Two Late-Breaking Abstracts for E-Poster Presentation at the 51st Annual European Society for Dermatological Research MeetingVIEW MORE
Webcast and Presentations R&D Day 2022
In September 2022, ASLAN hosted an R&D Day on eblasakimab featuring Key Opinion Leaders Peter Lio MD (Northwestern University) and Shawn Kwatra MD PhD (Johns Hopkins University). To access the presentation materials, please follow this link.
ASLAN’s A4 webinar series: Aspects of Atopic Dermatitis and ASLAN004 (eblasakimab)
We hosted a series of dialogues with key opinion leaders in dermatology on the emerging Atopic Dermatitis (AD) landscape and ASLAN004 (eblasakimab). To request access to replays of the episodes from the A4 Series, please follow this link.